Full-Time

Director of Clinical Operations

Senseye

Senseye

11-50 employees

Smartphone-based PTSD diagnostics via eye biomarkers

Compensation Overview

$180k - $205k/yr

+ Stock option plan

Austin, TX, USA

In Person

Bachelor's, Master's, PhD

Category
Biology & Biotech (1)

Get referred to Senseye

See people who can refer or advise you

Requirements
  • Bachelor’s degree in a relevant field.
  • 5–8+ years of experience in clinical research, clinical operations, or clinical affairs.
  • Demonstrated experience leading or managing clinical teams or vendors, such as contract research organizations.
  • Experience in medtech, digital health, or neurotechnology.
  • Familiarity with Food and Drug Administration clinical and regulatory pathways.
  • Strong cross-functional collaboration and communication skills.
Responsibilities
  • Lead and execute clinical studies from early validation through pivotal trials.
  • Oversee and mentor clinical operations team members, fostering strong execution and professional development.
  • Manage and coordinate external partners, including contract research organizations, sites, and investigators.
  • Design study protocols and generate evidence to support regulatory and commercial goals.
  • Collaborate cross-functionally with Research, Artificial Intelligence, and Regulatory teams.
  • Support Food and Drug Administration submissions and clinical documentation.
  • Contribute to scientific publications and presentations.
  • Ensure compliance with Good Clinical Practice and applicable regulations.
Desired Qualifications
  • Master’s or PhD preferred.
  • Experience in mental health or neuroscience.
  • Background in digital biomarkers or artificial-intelligence-driven diagnostics.
  • Startup or high-growth company experience.
  • Experience building or scaling clinical operations functions.

Senseye creates a Software as a Medical Device for mental health diagnosis, starting with PTSD. It uses a smartphone app to record eye responses with the front camera while users perform simple visual tasks, extracting digital biomarkers from pupil gaze and iris biomechanics. A proprietary machine learning algorithm analyzes these signals to produce a diagnostic report with a severity score within minutes, without specialized hardware. Its goal is to replace subjective self-reports and expand to a broader panel of mental health disorders (like MDD and GAD) for baseline assessment and monitoring of treatment outcomes.

Company Size

11-50

Company Stage

Series A

Total Funding

$8M

Headquarters

Bellflower, California

Founded

2015

Get referred to Senseye

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Senseye published 2026 peer-reviewed PTSD findings and two ADAA feasibility posters.
  • Topcon announced on 2025-09-09 a strategic investment, signaling commercial validation.
  • Senseye says it is progressing toward FDA-regulated medical use as of 2026-07-28.

What critics are saying

  • Senseye still lacks FDA authorization, leaving sales dependent on research use and pilots.
  • The 2026 veteran study enrolled only 38 patients, exposing fragile evidence for scale.
  • If FDA rejects Senseye's SaMD, the company loses its diagnostic business model.

What makes Senseye unique

  • Senseye's smartphone eye-biomarker platform measures PTSD without trauma disclosure, unlike questionnaires.
  • Its 2026 study showed iPhone pupillometry tracked PTSD severity in 38 veterans.
  • Topcon's 2025 strategic investment connects Senseye to ocular-data distribution and Harmony integration.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Stock Options

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Health Insurance

Dental Insurance

Vision Insurance

Disability Insurance

Life Insurance

Commuter Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
Topcon Healthcare, Inc.
Sep 9th, 2025
Topcon Healthcare, Inc. makes Strategic Investment in Senseye, Inc. to Advance Mental Health Diagnostics Through Ocular Biomarkers

Topcon Healthcare, Inc. makes strategic investment in Senseye, Inc. to advance mental health diagnostics through ocular biomarkers.

Eyewire
Sep 9th, 2025
Topcon Invests in Senseye for Eye-Based Mental Health Diagnostics

Topcon Healthcare has invested in Senseye, which is developing a mental health diagnostic platform using ocular biomarkers. Senseye's technology employs AI to analyze eye movements via smartphone cameras, aiding in diagnosing PTSD, MDD, and GAD. This investment marks Topcon's first foray into mental health, aiming to integrate Senseye's tech into its Harmony platform for a comprehensive view of patients' health. Financial terms were not disclosed.

Eyewire
Sep 9th, 2025
Topcon Healthcare Invests in Senseye to Advance Mental Health Diagnostics Through the Eye - Eyewire+

Topcon Healthcare announced a strategic investment in Senseye, which is developing a mental health diagnostic platform powered by ocular biomarke

LSE Europe Summit
Apr 18th, 2025
AI in Diagnostics: Opportunities for Transformation

For Zakariaie, whose company Senseye is developing AI tools for behavioral health, the key is intentional dataset design.

Trending Topics
Nov 28th, 2023
Ai Is So Much More Than Just Chatgpt – And This Investor Proves It

Kinled is renowned as a life sciences and financial technology investor, with a portfolio of over 125 investments. Within their portfolio are nearly 50 companies specialised in cutting edge digital technology. The advent of AI has altered the investment strategy of Patrick Aisher, Chairman of Hong Kong-based Kinled Holding Limited, who has established a global investment network. “Approximately 25% of our technology portfolio is directly involved in Artificial Intelligence applications”, says Aisher. “In reality, the use of massive computational power in life sciences and molecular drug discovery has been standard for many years, and this type of approach is now being applied to other industries. Kinled was an early investor in the first-ever FDA-approved AI diagnostic platform, and now has AI and machine-learning investments across multiple industries.”